TTrialPathMatch Me to Trials
← Back to trials
RecruitingBladder CancerUrothelial Carcinoma (UC)Hematuria

Specimen Collection for Validation of UroAmp: A Next Generation Sequencing Platform for Detection and Surveillance of Bladder Cancer

Eligible age

18+ yrs

Accepts

All genders

Locations

10 states

Healthy volunteers

No

See if you qualify for this study

Answer a few quick questions about your location and health. Takes about a minute.

Check my eligibility →

About this study

This is a prospective, multicenter observational study designed to collect urine and tumor biospecimens and associated clinical data from patients undergoing evaluation, treatment, or surveillance for urothelial carcinoma.

Sponsor: Convergent Genomics, Inc.

You may qualify if…

  • ✓ GROUP 1: Bladder Cancer and/or Upper Tract UCC
  • ✓ Male or female ≥ 18 years of age who are scheduled for transurethral resection of bladder tumor (TURBT) and/or biopsy of urinary tract or
  • ✓ Patients on surveillance who are negative for recurrence or tumor at the time of study enrollment but have had previous urothelial cell carcinoma (UCC) or
  • ✓ Patients with muscle invasive bladder cancer (MIBC) or non-muscle invasive bladder cancer (NMIBC) scheduled for NAC and/or subsequent radical cystectomy (RC)
  • ✓ Able to provide consent prior to diagnostic TURBT, nephroureterectomy, or administration of NAC and/or RC
  • ✓ Able to provide at least 20cc urine. If patient cannot void sufficient volume of urine, urologist can pull urine from the bladder via catheter or cystoscope. Urine should not be collected immediately after resection
  • ✓ Participation in other bladder cancer studies is allowed. Experimental therapy must be documented in the case report forms
  • ✓ GROUP 2: Hematuria Controls

You may not qualify if…

  • ✕ GROUP 1: Bladder Cancer and/or Upper Tract UCC
  • ✕ Clinical, symptomatic urinary tract infection at time of initial urine collection
  • ✕ Unable to provide adequate urine sample
  • ✕ GROUP 2: Hematuria Controls
  • ✕ \- Evidence and/or History of bladder cancer, upper tract UCC, kidney cancer and/or prostate cancer at the time of collection

Where it's recruiting

California

Oceanside · San Diego · San Jose

Illinois

Chicago · Grayslake · Mount Prospect · Niles …

Maryland

Hanover

Michigan

Royal Oak

Nevada

Las Vegas

New York

New York

Ohio

Cincinnati

Tennessee

Nashville

Texas

Austin · Dallas · San Antonio

Virginia

Virginia Beach

Source: ClinicalTrials.gov · NCT07673016 · last updated 2026-06-29

Specimen Collection for Validation of UroAmp: A Next Generation Sequen · TrialPath